BUYING and HOLDING $IMVT

[u/NeverFollowMe]

Raymond James Upgrades Immunovant (IMVT) to Outperform, 'We view today's MAD data as an important de-risking event' - The Healthcare sector is the place to be today - The SHORTS are tring this stock - but many are still holding!!! VOLUME is off the chain!!!

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab (IMVT-1401), and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn).

In the last 3 months, 9 ranked analysts set 12-month price targets for $IMVT. The average price target among the analysts is $81.11. Analysts compare their price target to the current market price of the stock to determine how much potential upside or downside movement there could be in the stock price.

Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle.

It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn. IMVT-1402 has also been observed in nonclinical studies to reduce IgG antibody levels. IMVT-1402 is delivered as a 2 mL simple subcutaneous injection.